Biogen Statement to SMA Community re: EAP for SMA Type 1 in England, Wales and Northern Ireland

01 November 2018

Despite our urgent request, Biogen has not extended the cut off for this programme to 1st December. It ends now for any newly diagnosed infants. We will continue to work with Muscular Dystrophy UK, TreatSMA, and clinicians to do all we can to ensure NHS England, NICE and Biogen find a long-term solution as a matter of urgency.

Families facing a new diagnosis may though have access to the AveXis-101 gene therapy clinical trials at GOSH or Newcastle. Contact details and information can be found here.

Read Biogen's statement